CD122-targetted IL-2 signals cause acute and selective apoptosis of B cells in Peyer's Patches.
Animals
Antibodies, Monoclonal
/ administration & dosage
B-Lymphocytes
/ cytology
Biological Availability
Cell Survival
/ drug effects
Complex Mixtures
/ administration & dosage
Female
Half-Life
Interleukin-2
/ antagonists & inhibitors
Interleukin-2 Receptor beta Subunit
/ metabolism
Mice
Peyer's Patches
/ cytology
Recombinant Proteins
/ administration & dosage
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 07 2020
29 07 2020
Historique:
received:
20
04
2020
accepted:
14
07
2020
entrez:
31
7
2020
pubmed:
31
7
2020
medline:
17
12
2020
Statut:
epublish
Résumé
Interleukin-2 (IL-2) has both pro- and anti-inflammatory properties that have been harnessed clinically and that are used experimentally to modulate leukocyte subsets in vivo. In mice, the bioavailability and half-life of IL-2 in vivo can be increased by complexing recombinant IL-2 with different clones of anti-IL-2 monoclonal antibodies that differentially target the cytokine to cells expressing different kinds of IL-2 receptors. While the impacts of systemic IL-2: anti-IL-2 antibody complex (IL-2C) administration are well-defined in the spleen and peripheral lymph nodes, how immune cells in the gut and gut-associated lymphoid tissues respond to IL-2C is not well characterized. Here, we analyze how major leukocyte populations in these tissues respond to IL-2C. We find that IL-2C targeting cells expressing IL-2 receptor beta cause an acute decrease in cellularity of Peyer's Patches while cell numbers in the lamina propria and intraepithelial lymphocytes are unaffected. Cell contraction in Peyer's Patches is associated with the apoptosis of multiple B cell subsets. Our results are important to consider for understanding off-target impacts of IL-2C regimes in experimental models and for considering how IL-2 may contribute to the etiology or severity of gut-associated conditions such as Crohn's Disease.
Identifiants
pubmed: 32728053
doi: 10.1038/s41598-020-69632-5
pii: 10.1038/s41598-020-69632-5
pmc: PMC7391758
doi:
Substances chimiques
Antibodies, Monoclonal
0
Complex Mixtures
0
Il2rb protein, mouse
0
Interleukin-2
0
Interleukin-2 Receptor beta Subunit
0
Recombinant Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12668Références
Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180–190. https://doi.org/10.1038/nri3156 (2012).
doi: 10.1038/nri3156
pubmed: 22343569
Malek, T. R. The biology of interleukin-2. Annu. Rev. Immunol. 26, 453–479. https://doi.org/10.1146/annurev.immunol.26.021607.090357 (2008).
doi: 10.1146/annurev.immunol.26.021607.090357
pubmed: 18062768
Jiang, T., Zhou, C. & Ren, S. Role of IL-2 in cancer immunotherapy. Oncoimmunology 5, e1163462. https://doi.org/10.1080/2162402X.2016.1163462 (2016).
doi: 10.1080/2162402X.2016.1163462
pubmed: 27471638
pmcid: 4938354
Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458. https://doi.org/10.4049/jimmunol.1490019 (2014).
doi: 10.4049/jimmunol.1490019
pubmed: 6293462
pmcid: 6293462
Klatzmann, D. & Abbas, A. K. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat. Rev. Immunol. 15, 283–294. https://doi.org/10.1038/nri3823 (2015).
doi: 10.1038/nri3823
pubmed: 25882245
Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D. & Sprent, J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924–1927. https://doi.org/10.1126/science.1122927 (2006).
doi: 10.1126/science.1122927
pubmed: 16484453
Tomala, J. & Kovar, M. IL-2/anti-IL-2 mAb immunocomplexes: a renascence of IL-2 in cancer immunotherapy? Oncoimmunology 5, e1102829. https://doi.org/10.1080/2162402X.2015.1102829 (2016).
doi: 10.1080/2162402X.2015.1102829
pubmed: 27141363
Schwartz, R. N., Stover, L. & Dutcher, J. P. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 16, 11–20 (2002).
Ebrahimpour, S. et al. Elevated levels of IL-2 and IL-21 produced by CD4+T cells in inflammatory bowel disease. J. Biol. Regul. Homeost. Agents 31, 279–287 (2017).
pubmed: 28685527
Katz, L. H. et al. Expression of IL-2, IL-17 and TNF-alpha in patients with Crohn’s disease treated with anti-TNF antibodies. Clin. Res. Hepatol. Gastroenterol. 38, 491–498. https://doi.org/10.1016/j.clinre.2014.01.010 (2014).
doi: 10.1016/j.clinre.2014.01.010
pubmed: 24613656
Kameyama, K. et al. IL-2 is positively involved in the development of colitogenic CD4+ IL-7R alpha high memory T cells in chronic colitis. Eur. J. Immunol. 40, 2423–2436. https://doi.org/10.1002/eji.200939764 (2010).
doi: 10.1002/eji.200939764
pubmed: 20623548
McKinstry, K. K. et al. Effector CD4 T-cell transition to memory requires late cognate interactions that induce autocrine IL-2. Nat. Commun. 5, 5377. https://doi.org/10.1038/ncomms6377 (2014).
doi: 10.1038/ncomms6377
pubmed: 25369785
pmcid: 4223689
Strutt, T. M. et al. IL-15 supports the generation of protective lung-resident memory CD4 T cells. Mucosal Immunol. 11, 668–680. https://doi.org/10.1038/mi.2017.101 (2018).
doi: 10.1038/mi.2017.101
pubmed: 29186108
McKinstry, K. K. et al. Memory CD4 T cell-derived IL-2 synergizes with viral infection to exacerbate lung inflammation. PLoS Pathog. 15, e1007989. https://doi.org/10.1371/journal.ppat.1007989 (2019).
doi: 10.1371/journal.ppat.1007989
pubmed: 31412088
pmcid: 6693742
Alam, F. et al. CD25-Targeted IL-2 signals promote improved outcomes of influenza infection and boost memory CD4 T cell formation. J. Immunol. https://doi.org/10.4049/jimmunol.2000205 (2020).
doi: 10.4049/jimmunol.2000205
pubmed: 32376651
Han, K. H. et al. Effects of stimulating interleukin-2/anti-interleukin-2 antibody complexes on renal cell carcinoma. BMC Urol. 16, 2. https://doi.org/10.1186/s12894-016-0121-2 (2016).
doi: 10.1186/s12894-016-0121-2
pubmed: 26772545
pmcid: 4715282
Morrison, V. L., Barr, T. A., Brown, S. & Gray, D. TLR-mediated loss of CD62L focuses B cell traffic to the spleen during Salmonella typhimurium infection. J. Immunol. 185, 2737–2746. https://doi.org/10.4049/jimmunol.1000758 (2010).
doi: 10.4049/jimmunol.1000758
pubmed: 20660707
pmcid: 3745606
Usami, J. et al. Apoptosis by CD95 (Fas)-dependent and -independent mechanisms in Peyer’s patch lymphocytes in murine retrovirus-induced immunodeficiency syndrome. J. Virol. 70, 8917–8925 (1996).
doi: 10.1128/JVI.70.12.8917-8925.1996
Ayala, A. et al. Increased mucosal B-lymphocyte apoptosis during polymicrobial sepsis is a Fas ligand but not an endotoxin-mediated process. Blood 91, 1362–1372 (1998).
doi: 10.1182/blood.V91.4.1362
Depper, J. M. et al. Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc. Natl. Acad. Sci. U S A 82, 4230–4234. https://doi.org/10.1073/pnas.82.12.4230 (1985).
doi: 10.1073/pnas.82.12.4230
pubmed: 2987968
pmcid: 397970
Amu, S., Gjertsson, I., Tarkowski, A. & Brisslert, M. B-cell CD25 expression in murine primary and secondary lymphoid tissue. Scand. J. Immunol. 64, 482–492. https://doi.org/10.1111/j.1365-3083.2006.01832.x (2006).
doi: 10.1111/j.1365-3083.2006.01832.x
pubmed: 17032240
Ortega, G., Robb, R. J., Shevach, E. M. & Malek, T. R. The murine IL 2 receptor. I. Monoclonal antibodies that define distinct functional epitopes on activated T cells and react with activated B cells. J. Immunol. 133, 1970–1975 (1984).
pubmed: 6206144
Lowenthal, J. W., Zubler, R. H., Nabholz, M. & MacDonald, H. R. Similarities between interleukin-2 receptor number and affinity on activated B and T lymphocytes. Nature 315, 669–672. https://doi.org/10.1038/315669a0 (1985).
doi: 10.1038/315669a0
pubmed: 3925347
Tseng, J. A population of resting IgM-IgD double-bearing lymphocytes in Peyer’s patches: the major precursor cells for IgA plasma cells in the gut lamina propria. J. Immunol. 132, 2730–2735 (1984).
pubmed: 6609959
Fevery, S. et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia 21, 1451–1459. https://doi.org/10.1038/sj.leu.2404720 (2007).
doi: 10.1038/sj.leu.2404720
pubmed: 17508005
Van Kruiningen, H. J., Ganley, L. M. & Freda, B. J. The role of Peyer’s patches in the age-related incidence of Crohn’s disease. J. Clin. Gastroenterol. 25, 470–475. https://doi.org/10.1097/00004836-199709000-00017 (1997).
doi: 10.1097/00004836-199709000-00017
pubmed: 9412954
Ishii, H. et al. Peyer’s patches in the terminal ileum in ulcerative colitis: magnifying endoscopic findings. J. Clin. Biochem. Nutr. 46, 111–118. https://doi.org/10.3164/jcbn.09-77 (2010).
doi: 10.3164/jcbn.09-77
pubmed: 20216943
pmcid: 2831089
Ohman, L., Franzen, L., Rudolph, U., Birnbaumer, L. & Hornquist, E. H. Regression of Peyer’s patches in G alpha i2 deficient mice prior to colitis is associated with reduced expression of Bcl-2 and increased apoptosis. Gut 51, 392–397. https://doi.org/10.1136/gut.51.3.392 (2002).
doi: 10.1136/gut.51.3.392
pubmed: 12171962
pmcid: 1773369
Spahn, T. W. et al. Induction of colitis in mice deficient of Peyer’s patches and mesenteric lymph nodes is associated with increased disease severity and formation of colonic lymphoid patches. Am. J. Pathol. 161, 2273–2282. https://doi.org/10.1016/S0002-9440(10)64503-8 (2002).
doi: 10.1016/S0002-9440(10)64503-8
pubmed: 12466141
pmcid: 1850913
Cerutti, A. & Rescigno, M. The biology of intestinal immunoglobulin A responses. Immunity 28, 740–750. https://doi.org/10.1016/j.immuni.2008.05.001 (2008).
doi: 10.1016/j.immuni.2008.05.001
pubmed: 18549797
pmcid: 3057455
Goetz, M., Atreya, R., Ghalibafian, M., Galle, P. R. & Neurath, M. F. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm. Bowel Dis. 13, 1365–1368. https://doi.org/10.1002/ibd.20215 (2007).
doi: 10.1002/ibd.20215
pubmed: 17604367
El Fassi, D., Nielsen, C. H., Kjeldsen, J., Clemmensen, O. & Hegedus, L. Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves’ disease. Gut 57, 714–715. https://doi.org/10.1136/gut.2007.138305 (2008).
doi: 10.1136/gut.2007.138305
pubmed: 18408106
Lipka, S., Katz, S. & Crawford, J. M. Fulminant colitis following rituximab therapy. Gastroenterol. Hepatol. (N Y) 12, 58–60 (2016).
Wang, L. et al. T regulatory cells and B cells cooperate to form a regulatory loop that maintains gut homeostasis and suppresses dextran sulfate sodium-induced colitis. Mucosal Immunol. 8, 1297–1312. https://doi.org/10.1038/mi.2015.20 (2015).
doi: 10.1038/mi.2015.20
pubmed: 25807185
pmcid: 4583327
Panelli, M. C. et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Transl. Med. 2, 17. https://doi.org/10.1186/1479-5876-2-17 (2004).
doi: 10.1186/1479-5876-2-17
pubmed: 15175100
pmcid: 434535
Assier, E. et al. NK cells and polymorphonuclear neutrophils are both critical for IL-2-induced pulmonary vascular leak syndrome. J. Immunol. 172, 7661–7668 (2004).
doi: 10.4049/jimmunol.172.12.7661
Heidegger, S. et al. Virus-associated activation of innate immunity induces rapid disruption of Peyer’s patches in mice. Blood 122, 2591–2599. https://doi.org/10.1182/blood-2013-01-479311 (2013).
doi: 10.1182/blood-2013-01-479311
pubmed: 23823318
Krieg, C., Letourneau, S., Pantaleo, G. & Boyman, O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc. Natl. Acad. Sci. U S A 107, 11906–11911. https://doi.org/10.1073/pnas.1002569107 (2010).
doi: 10.1073/pnas.1002569107
pubmed: 20547866
pmcid: 2900642
Burger, C. & Vitetta, E. S. The response of B cells in spleen, Peyer’s patches, and lymph nodes to LPS and IL-4. Cell Immunol. 138, 35–43. https://doi.org/10.1016/0008-8749(91)90130-4 (1991).
doi: 10.1016/0008-8749(91)90130-4
pubmed: 1913841
Iwasaki, A. & Kelsall, B. L. Unique functions of CD11b+, CD8 alpha+, and double-negative Peyer’s patch dendritic cells. J. Immunol. 166, 4884–4890. https://doi.org/10.4049/jimmunol.166.8.4884 (2001).
doi: 10.4049/jimmunol.166.8.4884
pubmed: 11290765
McKinstry, K. K. et al. Rapid default transition of CD4 T cell effectors to functional memory cells. J. Exp. Med. 204, 2199–2211. https://doi.org/10.1084/jem.20070041 (2007).
doi: 10.1084/jem.20070041
pubmed: 17724126
pmcid: 2118696